Advertisement
U.S. markets closed

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE - NYSE Delayed Price. Currency in USD
125.96+0.79 (+0.63%)
At close: 04:00PM EDT
126.00 +0.04 (+0.03%)
After hours: 06:08PM EDT
  • Dividend

    ZBH announced a cash dividend of 0.24 with an ex-date of Mar. 27, 2024

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close125.17
Open125.27
Bid123.35 x 1000
Ask126.10 x 1100
Day's Range125.10 - 126.31
52 Week Range102.00 - 149.25
Volume877,109
Avg. Volume1,609,575
Market Cap25.832B
Beta (5Y Monthly)1.01
PE Ratio (TTM)25.86
EPS (TTM)4.87
Earnings DateApr 30, 2024 - May 06, 2024
Forward Dividend & Yield0.96 (0.76%)
Ex-Dividend DateMar 27, 2024
1y Target Est136.61
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ZBH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zimmer Biomet Holdings, Inc.
    Analyst Report: Zimmer Biomet Holdings, Inc.Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
    Rating
    Fair Value
    Economic Moat
    26 days agoMorningstar
View more